drugset / Trial / NCT00002748
Gene Therapy in Treating Children With Refractory or Recurrent Neuroblastoma
Phase 1
Completed
38 enrolled
St. Jude Children's Research Hospital
National Cancer Institute (NCI) · collab
Treatment
Summary
RATIONALE: Inserting the gene for interleukin-2 into a person's neuroblastoma cells may make the body build an immune response and kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of using interleukin-2 gene-modified neuroblastoma cells in treating children who have refractory or recurrent neuroblastoma.
Timeline
- Start
- 1991-12
- Primary completion
- 2007-08
- Completion
- 2007-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | gene-modified tumor cell vaccine therapy | Cell therapy | — | Subcutaneous |
| Background | interleukin-2 gene | Unknown | — | Subcutaneous |